Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience CHJ Lamers, S Sleijfer, AG Vulto, WHJ Kruit, M Kliffen, R Debets, ... Journal of Clinical Oncology 24 (13), e20-e22, 2006 | 1135 | 2006 |
Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity CHJ Lamers, S Sleijfer, S Van Steenbergen, P Van Elzakker, ... Molecular therapy 21 (4), 904-912, 2013 | 816 | 2013 |
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types T Rafnar, P Sulem, SN Stacey, F Geller, J Gudmundsson, A Sigurdsson, ... Nature genetics 41 (2), 221-227, 2009 | 706 | 2009 |
Immune responses to transgene and retroviral vector in patients treated with ex vivo–engineered T cells CHJ Lamers, R Willemsen, P van Elzakker, ... Blood, The Journal of the American Society of Hematology 117 (1), 72-82, 2011 | 432 | 2011 |
PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer J Dulos, GJ Carven, SJ van Boxtel, S Evers, LJA Driessen-Engels, ... Journal of immunotherapy 35 (2), 169-178, 2012 | 338 | 2012 |
Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13. 3 MP Purdue, M Johansson, D Zelenika, JR Toro, G Scelo, LE Moore, ... Nature genetics 43 (1), 60-65, 2011 | 316 | 2011 |
Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy AB Stillebroer, PFA Mulders, OC Boerman, WJG Oyen, E Oosterwijk European urology 58 (1), 75-83, 2010 | 257 | 2010 |
Expression of HIF-1α, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer SJ Kim, ZN Rabbani, MW Dewhirst, Z Vujaskovic, RT Vollmer, ... Lung cancer 49 (3), 325-335, 2005 | 251 | 2005 |
Molecular cloning and immunogenicity of renal cell carcinoma‐associated antigen G250 K Grabmaier, JLM Vissers, MCA De Weijert, JC Oosterwijk‐Wakka, ... International journal of cancer 85 (6), 865-870, 2000 | 243 | 2000 |
Strict regulation of CAIXG250/MN by HIF-1α in clear cell renal cell carcinoma K Grabmaier, MCA de Weijert, GW Verhaegh, JA Schalken, E Oosterwijk Oncogene 23 (33), 5624-5631, 2004 | 234 | 2004 |
Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer K Buffen, M Oosting, J Quintin, A Ng, J Kleinnijenhuis, V Kumar, ... PLoS pathogens 10 (10), e1004485, 2014 | 231 | 2014 |
Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. MG Steffens, OC Boerman, JC Oosterwijk-Wakka, GO Oosterhof, ... Journal of Clinical Oncology 15 (4), 1529-1537, 1997 | 228 | 1997 |
A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients I Bleumer, A Knuth, E Oosterwijk, R Hofmann, Z Varga, C Lamers, W Kruit, ... British journal of cancer 90 (5), 985-990, 2004 | 220 | 2004 |
Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. E Oosterwijk, NH Bander, CR Divgi, S Welt, JC Wakka, RD Finn, ... Journal of clinical oncology 11 (4), 738-750, 1993 | 215 | 1993 |
The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2. 1-restricted epitope recognized by cytotoxic T lymphocytes JLM Vissers, IJM De Vries, MWJ Schreurs, LPH Engelen, E Oosterwijk, ... Cancer Research 59 (21), 5554-5559, 1999 | 210 | 1999 |
Immunotherapy for renal cell carcinoma I Bleumer, E Oosterwijk, P De Mulder, PFA Mulders European urology 44 (1), 65-75, 2003 | 203 | 2003 |
Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. CR Divgi, NH Bander, AM Scott, JA O'Donoghue, G Sgouros, S Welt, ... Clinical cancer research: an official journal of the American Association …, 1998 | 203 | 1998 |
MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas H Uemura, Y Nakagawa, K Yoshida, S Saga, K Yoshikawa, Y Hirao, ... British journal of cancer 81 (4), 741-746, 1999 | 199 | 1999 |
Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re AH Brouwers, JEM van Eerd, C Frielink, E Oosterwijk, WJG Oyen, ... Journal of Nuclear Medicine 45 (2), 327-337, 2004 | 174 | 2004 |
Aminopeptidase A is a functional target in angiogenic blood vessels S Marchiò, J Lahdenranta, RO Schlingemann, D Valdembri, P Wesseling, ... Cancer cell 5 (2), 151-162, 2004 | 161 | 2004 |